@article {7746,
	title = {Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: A single institution experience},
	journal = {Tumori},
	volume = {97},
	year = {2011},
	note = {Cited By :11Export Date: 21 February 2017},
	month = {2011},
	pages = {25 - 29},
	abstract = {Background and aims. Primary malignant peritoneal mesothelioma is a rare malignancy with an unfavorable prognosis. Pemetrexed has proven effective in the treatment of malignant mesothelioma, alone or in combination with platinum agents. In the present study, chemo-na{\"\i}ve patients were evaluated for the efficacy and safety of the pemetrexed-cisplatin combination. Methods. Six patients with diffuse peritoneal mesothelioma were treated with 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2). Chemotherapy was administered on an outpatient basis every 3 weeks. Results. Complete response was observed in 2 patients (33\%) and partial response was observed in 3 patients (50\%). The estimated median overall survival was 24 months and the estimated median time to disease progression was 9.5 months. The regimen was well tolerated. Conclusions. Though our data reflect a small sample size, pemetrexed plus cisplatin accomplished a particularly high clinical benefit rate on chemo-na{\"\i}ve patients. Free full text available at www.tumorionline.it.},
	keywords = {Cisplatin, Malignant peritoneal mesothelioma, Pemetrexed},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953869990\&doi=10.1700\%2f611.7133\&partnerID=40\&md5=29ff6d20618a90f1e6f0e9ce036d16e5},
	author = {Lainakis, G. and Zagouri, F. and Kastritis, E. and Sergentanis, T.N. and Bozas, G. and Dimopoulos, M.A. and Papadimitriou, C.A.}
}
